LinqAlpha Wins Best AI Solution at the 2026 Hedge Fund Services Awards
The Hedge Fund Services Awards recognize the service providers driving innovation, operational excellence, and sustainable growth across the hedge fund industry. Winners are selected by an independent panel of senior industry leaders, including COOs, CFOs, CTOs, CCOs, and General Counsel from leading investment firms.
LinqAlpha was recognized for its innovative application of AI to institutional investment workflows. Its multi-agent platform helps investment firms transform fragmented market intelligence, research, meetings, and proprietary data into a searchable institutional knowledge base.
LinqAlpha supports investment workflows across asset classes, including equities, macro, credit, and multi-asset strategies. More than 70 financial institutions across
"This award is a strong validation of our vision to build the AI operating system for public markets," said
About LinqAlpha
LinqAlpha is a
LinqAlpha has been featured by TechCrunch and Forbes for outperforming NVIDIA and OpenAI in industry benchmark evaluations. Today, more than 70 financial institutions across
For more information, visit www.linqalpha.com.
About With Intelligence
With Intelligence is a leading provider of investment intelligence, data, events, and networking opportunities for the global asset management industry. The Hedge Fund Services Awards recognize outstanding service providers delivering innovation, client service, and business impact across the investment ecosystem.
View original content to download multimedia:https://www.prnewswire.com/news-releases/linqalpha-wins-best-ai-solution-at-the-2026-hedge-fund-services-awards-302809612.html
SOURCE LinqAlpha
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robo.ai Inc. Announces Appointment of Wang Hao, Senior Executive Officer of UAE Independent Digital Asset Custodian Changer.ae, as Independent Director
- Form-8.3 APTITUDE SOFTWARE GROUP PLC - 20 08 2026 - (CGAML)
- Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Goldman Sachs, Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share